Last week, Trulieve Cannabis (OTC: TCNNF) (NYSE:TRLV) became the first U.S. cannabis operator to list on the New York Stock Exchange. The stock is now trading under the symbol “TRLV.”
Although a publicly traded company moving up to the NYSE is not uncommon, it is in the cannabis industry.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a “Double Down” signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same “Total Conviction” signal is flashing for a company 1/100th the size of Nvidia. Continue »
You see, until now, major U.S. cannabis companies were largely shut out of the NYSE and Nasdaq Stock Market because marijuana remained federally illegal and was deemed a Schedule I drug, a classification reserved for the most addictive and dangerous drugs. As a result, many of these companies traded on Canadian exchanges or less stringently regulated over-the-counter (OTC) markets. That limited visibility and reduced liquidity kept most institutional investors on the sidelines.
But things are changing.
Schedule III is the catalyst
Trulieve’s NYSE debut became possible after the U.S. government moved state-licensed medical marijuana businesses into Schedule III designation, which is reserved for drugs with possible therapeutical uses. This change creates a pathway for federal registration of medical cannabis operators.
To qualify, Trulieve restructured its business so that the company listed on the exchange consists entirely of medical marijuana operations.
Trulieve didn’t, however, abandon the recreational cannabis market. That business still exists and can continue generating revenue, but it’s not included in the NYSE-listed entity’s financial structure. In other words, Trulieve created a corporate structure that satisfies exchange requirements while preserving its economic exposure to the broader cannabis market.
What happens next?
If other operators can follow a similar path, the entire industry’s investor base could expand dramatically.
The truth is, institutional investors, pension funds, mutual funds, and large wealth managers either cann’t or won’t invest in OTC-listed securities. Major exchange listings remove one of those barriers. And greater institutional participation generally leads to higher trading volume, more liquidity, greater analyst coverage, and easier access to capital.
To be sure, those factors don’t guarantee higher stock prices, but they can improve market efficiency and reduce some of the structural disadvantages cannabis companies have faced for years.
